Wir sind mit live! Mehr erfahren

Henry Schein

HSIC

Börsenwert 9,6 Mrd. $

86,38 USD

-0,61

0,7 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

85,82

-0,56

0,65 %

1 Tag

-0,7 %

5 Tage

2,64 %

1 Monat

-0,45 %

3 Monate

-2,13 %

6 Monate

11,88 %

Seit Jahresbeginn

12,44 %

1 Jahr

39,26 %

5 Jahre

12,87 %

10 Jahre

43,77 %

Profil: Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.

Mitarbeiter: 25.000

Gesundheitswesen Medizinischer Großhandel

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 64,1 %

Neutral 35,9 %

Negativ 0 %

Zacks Investment Research

Henry Schein (HSIC) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Henry Schein (HSIC) is a Top-Ranked Value Stock: Should You Buy?

Henry Schein Announces Chief Financial Officer Leadership Transition

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, Inc. (NYSE: ITT), has been named the Company's Senior Vice President and Chief Financial Officer effective November 4, 2026. Mr. Caprais will join the Henry Schein Leadership Team (HSLT) and report to Frederick M. Lowery, Chief Executive Officer of Henry Schein. To support a structured transition, Mr. Caprais will initially se.

Henry Schein Announces Chief Financial Officer Leadership Transition

Zacks Investment Research

HSIC or MMSI: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Henry Schein (HSIC) or Merit Medical (MMSI). But which of these two stocks presents investors with the better value opportunity right now?

HSIC or MMSI: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Should Value Investors Buy Henry Schein (HSIC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Henry Schein (HSIC) Stock?

Henry Schein Cares Marks 25 Years of Helping Health Happen®

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein Cares, Henry Schein, Inc.'s global corporate citizenship program, is celebrating a quarter century of bringing together Team Schein Members, customers, supplier partners, healthcare professionals, nonprofit organizations, and communities to help make the world healthier. Today, Henry Schein Cares reflects the Company's broader approach to corporate citizenship through five interconnected pillars: Catalyzing Healthcare Access; Advancing Policies, Sol.

Henry Schein Cares Marks 25 Years of Helping Health Happen®

Zacks Investment Research

Here's Why Henry Schein (HSIC) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Henry Schein (HSIC) is a Strong Growth Stock

Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher

Henry Schein remains a dominant global provider of dental and medical practitioner supplies, with recent share price outperformance versus the S&P 500. HSIC delivered strong Q2 results: revenue up 6.7% to $3.46B, net income and cash flow both meaningfully improved, and all business segments showed growth. Management raised 2026 guidance, now expecting 4.5–5.5% revenue growth and adjusted EPS of $5.29–$5.39, reflecting ongoing operational momentum.

Henry Schein Still Gives Me A Reason To Smile After This Nice Move Higher

Zacks Investment Research

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Zacks Investment Research

What Makes Henry Schein (HSIC) a New Buy Stock

Henry Schein (HSIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Henry Schein (HSIC) a New Buy Stock

Zacks Investment Research

HSIC or SAUHY: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks offers value investors a better bang for their buck right now?

HSIC or SAUHY: Which Is the Better Value Stock Right Now?

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt